Bear Stearns cautions on MedImmune

Bear Stearns analyst Monica Orbe said Synagis, MedImmune, Inc.'s flagship product for the prevention of respiratory infection in premature infants, has been showing disappointing sales trends. Bear Stearns said one of the key issues that plagued Synagis sales in May was MedImmune's removal of Caremark as a distributor. Shares of the Gaithersburg, Md.-based pharmaceutical company were up $0.37, or 1.15%, at $31.92 on volume of 2,333,397 shares versus the three-month running average of 2,350,230 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.